Researchers in Brazil and Spain packaged rapamycin, a well-known mTOR-inhibiting longevity and anticancer drug, inside PEG-coated human serum albumin nanoparticles to solve rapamycin’s chronic problem of poor solubility and instability. The particles were small, uniform, negatively charged, and loaded more than 70 percent of the drug they were given. They released their cargo slowly over 24 hours, killed breast cancer cells in a dish about as well as free rapamycin, and, most eye-catchingly, extended the average lifespan of the worm Caenorhabditis elegans by around 70 percent, well beyond the roughly 27 percent from free rapamycin. The work is a proof-of-concept delivery study, not a mammalian aging trial, and the size of the lifespan effect deserves cautious reading because the untreated worms lived shorter than the published average for their species.
Rapamycin is one of the most studied molecules in aging science. It switches off mTOR, a master growth sensor, and in doing so mimics some of the effects of caloric restriction while extending lifespan in yeast, flies, worms, and mice. The catch has always been the drug itself. Rapamycin barely dissolves in water (about 2.6 micrograms per milliliter), degrades when exposed to light, heat, and pH swings, and once injected it hides inside red blood cells where it does little good. For a compound with so much therapeutic promise, getting a reliable dose into the body remains surprisingly hard.
A team led by groups at Sao Paulo State University in Brazil and the University of Navarra in Spain took a practical run at this problem. Rather than inventing a new drug, they built a better envelope for the old one. Using a standard desolvation method, they precipitated human serum albumin, the most abundant protein in blood, into nanoparticles around 180 to 200 nanometers across, then wrapped them in polyethylene glycol to help them slip past the body’s clearance systems. Albumin is attractive here because it is biodegradable, already used in approved cancer drugs such as Abraxane, and naturally drawn to receptors that tumors overexpress.
The engineering worked cleanly. The particles were uniform, carried a stable negative surface charge near minus 30 millivolts, and encapsulated more than 70 percent of the rapamycin, rising to about 81 percent at the higher drug loading. Instead of dumping the drug all at once, they released roughly a fifth in the first two hours and about 40 percent over a full day, a slow drip that free rapamycin, which diffused almost entirely within two hours, cannot provide.
The biology was where the story got interesting. In breast cancer cells, the loaded particles matched free rapamycin’s cell-killing power while showing no toxicity from the empty carrier itself. Then came the worms. Untreated C. elegans died off completely by day 17. Free rapamycin pushed average lifespan to 19 days. The albumin-packaged version pushed it to 26 days, an increase the authors describe as around 70 percent. Whether that magnitude survives scrutiny is a separate question, addressed below, but the direction is clear: encapsulation made rapamycin work harder.
Actionable Insights
The honest takeaway is that this is an early delivery study in cells and worms, so nobody should change what they put in their body based on it. There is no human, and no mammal, in this paper. What it does add to the longevity conversation is a reminder that how a compound is delivered can matter as much as the compound itself. The same rapamycin, simply wrapped differently, went from extending worm lifespan by about 27 percent to about 70 percent in the authors’ hands.
To put the effect size in plain terms: an effect size (Cohen’s d) measures how far apart two groups are relative to their natural spread, where 0.2 is small, 0.5 is medium, and 0.8 or above is large. The lifespan gap between wrapped rapamycin and untreated worms works out to a very large d (well above 3 on the reported numbers), but that figure is inflated because the study reported unusually tight variation across a handful of repeated experiments, not the true spread among individual worms. A more grounded reading is the raw numbers: about 11 extra days of median life for the worms, roughly a 70 percent gain, versus 4 extra days (about 27 percent) for plain rapamycin.
For a practically minded reader, the transferable idea is bioavailability, not a supplement recommendation. Rapamycin’s problem in real life is that little of it reaches its target in usable, sustained form. Formulation strategies that provide slow, steady release are an active and legitimate frontier.
Context and Source
- Open Access Paper: Evaluation of Human Serum Albumin Nanoparticles for Rapamycin Delivery.
- Authors and institutions: Camila Fernanda Rodero, Cristina Pangua, Jorge Morales Gracia, Melibea Berzosa Suner, Marcela Tavares Guiguer, Marlus Chorilli (corresponding), and Juan M. Irache. Affiliations are the School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara, Brazil, and the Department of Pharmaceutical Sciences, University of Navarra, Pamplona, Spain.
- Journal: ACS Omega (American Chemical Society).
- Impact evaluation: ACS Omega’s most recent Journal Impact Factor is approximately 3.7, and its CiteScore is reported in roughly the 5 to 7 range depending on source and year. Using the impact factor as the anchor: the impact score of this journal is approximately 3.7, evaluated against a typical high-end range of 0 to 60+ for top general science journals, therefore this is a Low-to-Medium impact journal.